HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.

Abstract
The CD30 ligand (CD30L) is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. Recent cloning of CD30L has enabled studies to explore its function and tissue distribution. For instance, recombinant CD30L has been shown to co-stimulate T cells and to act as mitogen for Hodgkin's disease (HD)-derived cell lines. The counter-receptor for CD30L, ie, CD30, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed-Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. In the present study, recombinant membrane-bound and soluble human CD30L were instrumental to raise a monoclonal antibody (M80) recognizing membrane-bound CD30L on transfected and native cells. With this reagent, a panel of cultured lymphoma-derived cell lines as well as primary normal, reactive, and HD-involved lymphoid tissues were examined for expression of CD30L by immunostaining and flow cytometry. In reactive lymphnodes and tonsils, CD30L was expressed by a small subset of lymphoid cells, histiocytes, and granulocytes. Higher levels of CD30L expression were noted in HD lesions among bystander cells; ie, T cells and granulocytes that surrounded H-RS cells. Native CD30L displayed at the cell surface was functionally active as shown by the ability of fixed granulocytes to interact with CD30+ cell lines. Moreover, CD30L was detectable, although to a lower staining intensity, in primary H-RS cells of all HD tissues investigated regardless of the histological subtype and the phenotype of H-RS cells (ie, CD30+/CD40+ versus CD30-/CD40+). Co-expression of CD30 and CD30L that was seen on H-RS cells of all, except the CD30- nodular lymphocyte predominant, subtypes of HD may point to the use of this pair of molecules in paracrine and/or autocrine mitogenic cell interactions. Monoclonal antibody M80 may thus represent a useful tool for studying CD30L expression on cultured cell lines and primary cells from normal, reactive, and malignant tissues.
AuthorsH J Gruss, A Pinto, A Gloghini, E Wehnes, B Wright, N Boiani, D Aldinucci, V Gattei, V Zagonel, C A Smith, M E Kadin, C von Schilling, R G Goodwin, F Herrmann, A Carbone
JournalThe American journal of pathology (Am J Pathol) Vol. 149 Issue 2 Pg. 469-81 (Aug 1996) ISSN: 0002-9440 [Print] United States
PMID8701986 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Surface
  • CD30 Ligand
  • Membrane Glycoproteins
  • Recombinant Proteins
  • TNFSF8 protein, human
Topics
  • Antibodies, Monoclonal (analysis)
  • Antigens, CD (biosynthesis)
  • Antigens, Surface (biosynthesis)
  • CD30 Ligand
  • Cell Count
  • Flow Cytometry
  • Granulocytes (immunology)
  • Hodgkin Disease (immunology, pathology)
  • Humans
  • Immunohistochemistry
  • Lymphoid Tissue (immunology, pathology)
  • Membrane Glycoproteins (biosynthesis)
  • Recombinant Proteins
  • Reed-Sternberg Cells (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: